Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. boosted its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 21.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,130 shares of the company’s stock after buying an additional 379 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Protagonist Therapeutics were worth $95,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. GSA Capital Partners LLP increased its position in shares of Protagonist Therapeutics by 179.8% during the first quarter. GSA Capital Partners LLP now owns 55,359 shares of the company’s stock worth $1,602,000 after purchasing an additional 35,571 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Protagonist Therapeutics by 1.2% during the first quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company’s stock worth $92,373,000 after buying an additional 39,055 shares in the last quarter. Seven Eight Capital LP grew its holdings in shares of Protagonist Therapeutics by 426.9% during the second quarter. Seven Eight Capital LP now owns 36,793 shares of the company’s stock worth $1,275,000 after buying an additional 29,810 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Protagonist Therapeutics by 9.1% in the second quarter. Bank of New York Mellon Corp now owns 204,299 shares of the company’s stock worth $7,079,000 after buying an additional 17,065 shares in the last quarter. Finally, Dark Forest Capital Management LP acquired a new position in Protagonist Therapeutics during the second quarter worth about $2,112,000. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

Protagonist Therapeutics Stock Performance

Shares of PTGX stock opened at $46.76 on Tuesday. The firm has a fifty day simple moving average of $45.19 and a 200-day simple moving average of $37.60. Protagonist Therapeutics, Inc. has a twelve month low of $14.78 and a twelve month high of $48.89. The company has a market capitalization of $2.75 billion, a PE ratio of 17.85 and a beta of 2.17.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.50) EPS for the quarter, meeting the consensus estimate of ($0.50). The business had revenue of $4.17 million during the quarter, compared to analyst estimates of $40.00 million. Equities research analysts predict that Protagonist Therapeutics, Inc. will post 2.32 EPS for the current year.

Insider Activity at Protagonist Therapeutics

In related news, CFO Asif Ali sold 14,203 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total transaction of $631,891.47. Following the sale, the chief financial officer now owns 34,960 shares of the company’s stock, valued at $1,555,370.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Protagonist Therapeutics news, Director William D. Waddill sold 8,000 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total value of $360,000.00. Following the completion of the transaction, the director now directly owns 12,000 shares in the company, valued at $540,000. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Asif Ali sold 14,203 shares of the firm’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total value of $631,891.47. Following the completion of the sale, the chief financial officer now directly owns 34,960 shares of the company’s stock, valued at approximately $1,555,370.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 5.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PTGX. TD Cowen raised shares of Protagonist Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 25th. JMP Securities reduced their target price on Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 7th. Wedbush restated an “outperform” rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a report on Monday. BTIG Research increased their target price on Protagonist Therapeutics from $41.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Finally, StockNews.com upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Protagonist Therapeutics has an average rating of “Buy” and a consensus price target of $53.57.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.